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2012).		Hence,	in	the	case	of	oseltamivir,	a	single	mutation	near	the	viral	neuraminidase	active	site	is	sufficient	to	attenuate	drug	binding	and	thereby	cause	resistance.	Thus,	alternative	classes	of	drugs	for	which	resistance	evolution	is	less	easily	achieved	have	garnered	interest.		One	promising	drug	is	favipiravir,	for	which	the	mechanism	of	action	is	related	to	the	selective	inhibition	of	viral	RNA-dependent	RNA	polymerase	(RdRp)	and	the	decrease	of	polymerase	fidelity,	which	results	in	an	increase	of	the	genome-wide	mutation	rate	in	IAV	(Baranovich	et	al.	2013;	Furuta	et	al.	2013).	To	our	knowledge,	no	study	to	date	has	found	evidence	for	successful	resistance	evolution	against	favipiravir.		This	may	suggest	either	that	resistance	is	complex	to	achieve	given	that	the	drug	effectively	targets	the	entire	genome	(and	thus	no	simple	genetic	solution	for	resistance	exists),	or	that	its	effect	is	so	strong	that	viral	populations	are	always	driven	to	extinction	prior	to	the	appearance	of	resistance	mutations.	The	field	of	evolutionary	theory	has	studied	the	effects	of	increasing	mutation	rates	on	asexual	populations	for	decades,	and	several	processes	may	be	invoked	that	lead	to	the	extinction	of	a	population	owing	to	an	artificially	increased	mutation	rate.	All	are	based	on	the	fact	that	the	majority	of	new	fitness-affecting	mutations	are	deleterious.	First,	Muller’s	ratchet	is	a	process	that	describes	the	decline	of	fitness	and	size	of	a	non-recombining	population,	owing	to	the	periodic	loss	of	the	most	fit	genotype	(Muller	1964;	Felsenstein	1974).	Theoretical	work	has	shown	that	the	speed	of	the	ratchet	is	determined	by	the	effective	population	size,	mutation	rate,	deleterious	selection	coefficient,	and	the	size	of	the	least-loaded	(i.e.,	most	fit)	class	at	mutation-selection	equilibrium	(Haigh	1978,	and	see	Gordo	and	
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Charlesworth	2000).	Although	the	ratchet	initially	leads	to	a	linear	accumulation	of	mutations	while	census	population	size	remains	constant,	it	may	ultimately	lead	to	the	rapid	extinction	of	the	population	due	to	what	is	referred	to	as	“mutational	meltdown”	(Lynch	et	al.	1990;	Lynch	et	al.	1993).	Under	high	mutation	rate	conditions,	the	loss	of	the	least-loaded	class	may	be	primarily	driven	by	mutation	rather	than	genetic	drift	(Lynch	et	al.	1993).	We	argue	that	the	process	of	mutational	meltdown	is	essentially	similar	to	“lethal	mutagenesis”,	a	term	that	has	subsequently	been	promoted	in	the	area	of	virology	(Bull	et	al.,	2007;	Wylie	&	Shakhnovich,	2012).	Both	occur	in	finite	populations	under	high	mutation	rates,	and	are	characterized	by	the	linear	accumulation	of	mutations	until	the	mean	viability	of	individuals	is	too	low	to	maintain	the	carrying	capacity,	at	which	point	both	population	size	and	fitness	deteriorate	rapidly,	leading	to	extinction.	They	differ	in	two	main	ways:	a	primary	focus	on	effective	population	size	(mutational	meltdown)	versus	census	population	size	(lethal	mutagenesis),	and	in	the	assumption	of	strong	(mutational	meltdown)	and	weak	(lethal	mutagenesis)	genetic	drift.	However,	extinction	is	eventually	driven	by	mutation	load	in	both,	and	the	models	are	thus	difficult	to	distinguish	empirically.		 Second,	although	beneficial	mutations	(e.g.,	mutations	conferring	drug	resistance	or	other	relative	growth	advantages)	will	also	become	more	frequent	under	increased	mutation	rates,	these	are	likely	to	occur	in	individuals	that	also	carry	deleterious	mutations,	which	may	prevent	or	slow	their	spread	in	the	population	in	the	absence	of	recombination.	This	effect,	termed	“weak-selection	Hill-Robertson	interference”	(WSHRI)	(Hill	and	Robertson	1966;	McVean	2000),	thus	may	also	serve	to	slow	the	evolution	of	resistance.		
.CC-BY-NC-ND 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was. http://dx.doi.org/10.1101/048934doi: bioRxiv preprint first posted online Apr. 16, 2016; 
	 7	
	 Finally,	the	extinction	of	populations	under	high	mutation	rate	conditions	has	been	frequently	discussed	in	the	area	of	virus	evolution	with	regard	to	the	concept	of	error	catastrophe	(Eigen	1971;	Eigen	2002;	Holmes	2003).	In	principle,	the	concept	of	error	catastrophe	is	similar	to	the	theories	of	mutational	meltdown	and	lethal	mutagenesis,	and	large	parts	of	the	theory	are	equivalent	(Wilke	2005).	However,	the	causal	mechanism	of	extinction	due	to	error	catastrophe	is	specifically	mutation	accumulation	beyond	the	“error	threshold”	above	which	the	evolutionary	dynamics	destabilize	and	the	genome	is	unable	to	maintain	the	required	information.	The	error	threshold	is	a	sharp	limit,	and	the	occurrence	of	error	catastrophe	is	not	limited	to	finite	populations.		 Here	we	present	data	from	in	vitro	selection	experiments	in	which	populations	of	IAV	were	evolved	in	the	presence	or	absence	of	favipiravir	treatment	and	compare	these	to	our	previous,	similar	experiment	using	oseltamivir	(Foll	et	al.	2014;	Renzette	et	al.	2014).	Results	indeed	demonstrate	that	favipiravir	induces	mutational	meltdown,	with	experimental	populations	exposed	to	escalating	drug	concentrations	eventually	becoming	extinct.	This	result	is	in	stark	contrast	to	the	populations	that	evolved	in	the	presence	of	escalating	amounts	of	oseltamivir,	in	which	resistance	mutations	arose	and	fixed	quickly	after	the	introduction	of	drug	pressure.	We	also	evaluate	different	concentrations	of	favipiravir	treatment,	quantifying	the	extent	necessary	to	induce	this	effect,	and	we	provide	the	first	evidence	for	potential	adaptation	to	favipiravir	under	a	constant	low	drug	concentration.	As	such,	this	experimental	set-up	allowed	us	to	directly	study	the	evolutionary	dynamics	of	IAV	in	different	drug	environments.	In	doing	so,	we	were	able	to	quantify	the	adaptive	process	with	respect	to	potential	beneficial	
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mutations	in	response	to	different	conditions	and	discuss	the	potential	for	evolutionary	rescue	(i.e.,	the	process	by	which	a	population	can	escape	extinction	in	a	novel	environment	through	rapid	adaptation;	Alexander	et	al.	2014).	Thus,	this	work	highlights	experimental	scenarios	of	clinical	relevance	of	both	successful	and	failed	evolutionary	rescue,	and	allows	us	to	observe	the	dynamics	of	mutational	meltdown	in	action.	Our	results	demonstrate	the	promise	of	drug-induced	mutational	meltdown	as	a	means	for	combating	viral	populations,	and	for	favipiravir	as	an	effective	strategy	against	IAV	in	particular.	Yet,	our	findings	also	raise	concerns	that	proper	drug	dosage	is	essential	for	effective	treatment.	By	discussing	our	results	with	respect	to	concepts	from	evolutionary	theory,	we	outline	prospects	for	the	better	prediction	of	the	evolutionary	response	of	pathogens	to	drug	pressure.			
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Population	dynamics	We	calculated	absolute	growth	rates	for	all	treatments	based	on	the	initial	and	final	population	size	(obtained	directly	before	and	after	virus	passaging)	as	given	by	the	MOI	and	the	PFU/ml,	respectively	(see	Supplementary	Table	1).	Note	that	the	latter	implicitly	assumes	that	each	formed	plaque	represents	a	single	infective	particle.	However,	given	the	generally	low	MOI	this	assumption	should	hold	true	for	our	data.	Following	Foll	et	al.	(2014),	we	assumed	that	for	all	treatments	the	population	grew	for	13	generations	at	constant	rate	r	per	passage,	yielding				 N(t) = N1 exprt .	Note	that	after	rearranging	and	solving	for	r,	the	corresponding	absolute	growth	rate	is	an	estimate	for	the	Malthusian	parameter	or	the	intrinsic	rate	of	increase	Chevin	(2010).	Selection	intensity	s	between	different	treatments	was	quantified	by	calculating s = rtreatment − rcontrol .	We	then	performed	a	linear	regression	via	ordinary	least	squares	of	the	growth	rates	r	and	selection	coefficients	against	time	(given	by	passage	number)	or	drug	concentration.	To	assess	whether	there	was	a	significant	linear	relationship	between	these	entities	(e.g.,	growth	rate	versus	initial	population	size;	see	Fig	3A),	we	performed	an	ordinary	t-test	under	the	null	hypotheses	of	no	significant	relationship	between	the	independent	(i.e.,	drug	
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where	x	and	y	are	the	allele	frequencies	at	two	time	points	separated	by	txy	generations,	z	=	(x+y)/2,	and !!n is	the	harmonic	mean	of	the	sample	sizes	nx	and	ny	at	those	time	points.	Additionally,	the	method	adapts	a	procedure	from	Change-Point	analysis	in	time-serial	data	to	detect	a	change	point	of	selection	along	the	allele	trajectory.	More	specifically,	a	statistic	from	the	cumulative	sum	control	chart	(CUSUM)	developed	by	Page	(1954)	is	integrated	into	the	ABC	method	to	characterize	the	time-sampled	trajectory	of	an	allele:		
! Si = Si−1 +(Fs 'i−Fs '), i =1,…,I 		where	the	index	i	refers	to	the	ith	time	point,	𝑆! = 0,	and	𝐹𝑠′	corresponds	to	the	mean	of	the	Fs’	over	all	pairs	of	consecutive	time	points.	The	change	point	SCP	is	the	sampling	time	point	with	the	maximal	absolute	value	of	Sm,	which	is	the	maximal	accumulation	of	difference	in	Fs’	from	its	average	value	in	the	time-sampled	trajectory:	
!SCP = argmaxi=0,...I |Si |. 	Using	these	two	summary	statistics	(Fs’	and	Scp),	CP-WFABC	jointly	estimates	the	temporal	position	of	a	change	point	as	well	as	the	strength	of	both	corresponding	selection	coefficients	(and	dominance	for	diploid	cases)	from	an	allele	trajectory.	Furthermore,	CP-WFABC	separates	allele	trajectories	characterized	by	a	single	selection	coefficient	from	those	with	changing	intensity	via	ABC	model	choice	(see	below).		The	same	data	sets	and	ascertainment	conditions	were	used	as	for	the	WFABC	analysis	described	above.	For	each	trajectory	of	interest,	we	tested	the	
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!p(M1 |D)p(M0 |D) = p(D|M1)p(M1)p(D|M0)p(M0) = B1,0 p(M1)p(M0) 	when	the	model	prior	p(M0)	is	equal	to	p(M1).	For	a	small	haploid	population,	as	in	the	case	for	IAV	in	this	experimental	setup	(i.e.,	Ne	on	the	order	of	hundreds),	
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For	the	lower	threshold	f	=	0.1%,	we	observed	a	strong	correlation	between	the	number	of	segregating	mutations	in	any	two	parallel	experiments	(see	Supplementary	Figure	2).	This	is	expected	if	sequencing	error	is	prevalent	at	this	frequency	threshold.	Hence,	differences	in	the	number	of	segregating	mutations	in	this	frequency	range	reflect	differences	in	coverage	and	sequencing	quality	across	passages	and	experiments.		For	the	high	threshold	f	=	1%,	we	observed	an	increase	in	the	number	of	segregating	mutations	with	time	in	the	favi1	and	favi2	populations,	consistent	with	an	increase	in	the	mutation	rate	due	to	favipiravir	treatment	(see	Figure	2A-B);	we	discuss	alternative	explanations,	including	different	or	changing	effective	population	sizes,	or	selected	mutations,	below.	In	every	population	associated	with	favipiravir	treatment	(favi1,	favi2,	constA,	constB,	withdrawalA),	the	average	number	of	segregating	mutations	was	higher	than	in	any	of	the	control	treatments.	Whereas	in	favi1	the	increased	number	of	mutations	was	clearly	visible	by	passage	8,	favi2	appeared	to	be	affected	even	at	very	low	concentrations.	These	differences	between	favi1	and	favi2	were	likely	due	to	the	constant	and	larger	bottleneck	sizes	between	passages	in	favi1	as	compared	with	favi2	(see	Materials	&	Methods,	Supplementary	Table	1).	The	observed	increase	in	the	number	of	segregating	mutations	was	roughly	2.5-fold	(excluding	the	last	passage	of	favi2)	which	is	in	agreement	with	previous	estimates	of	the	relative	increase	in	mutation	rate	under	favipiravir	treatment	(Baranovich	et	al.	2013).	For	constA,	constB	and	withdrawalA	(Figure	2	C-D,	Supplementary	Figure	2A)	the	number	of	segregating	mutations	remained	greater	than	that	of	the	control	for	the	most	part,	but	we	observed	no	further	increase	as	in	favi1	and	favi2.	As	the	experiment	ended	at	passage	17,	the	potential	recovery	of	the	
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To	study	the	effect	of	different	drug	conditions	on	the	growth	rates,	we	computed	relative	rates	as	the	difference	between	the	growth	rate	of	the	treatment	and	its	parallel	control,	 s = rtreatment − rcontrol .	This	accounts	for	effects	due	to	the	MDCK	cell	environment	and	the	size	of	the	imposed	passaging	bottlenecks,	which	were	generally	kept	identical	between	parallel	experiments	(see	Supplementary	Table	1).	We	observed	consistently	negative	relative	growth	rates	in	the	favi1	and	favi2	populations	(Figure	3C	and	Supplementary	Figure	4),	likely	due	to	the	challenging	effect	of	the	drug	on	the	population.	It	is	important	to	note	differences	in	the	experimental	procedure	in	the	favi2	population	and	its	parallel	control	from	that	of	all	other	populations	(see	also	Materials	&	Methods).	In	general,	bottleneck	sizes	(i.e.,	MOIs)	were	kept	constant	and	relatively	large,	and	new	passages	were	seeded	from	a	random	sample	of	the	previous	population.	However,	the	bottleneck	sizes	in	favi2	were	smaller	and	varied	greatly,	and	new	passages	were	seeded	based	on	the	fastest-growing	amongst	several	samples.	Therefore,	slightly	different	patterns	between	the	favi1	and	favi2	populations	are	expected	(such	as	the	higher	absolute	growth	rates	in	favi2	(see	Supplementary	Figure	4)).	Furthermore,	the	lower	MOIs	in	favi2	may	have	resulted	in	a	lower	probability	of	co-infection	of	cells,	and	thereby	in	a	lower	chance	of	virus	segment	reassortment	which,	analogous	to	recombination,	could	help	to	bring	together	co-adapted	segments	or	to	purge	deleterious	mutations	from	the	viral	genome;	a	potential	consequence	is	a	more	rapid	extinction	of	the	favi2	population.	Interestingly,	in	the	constA	population	(Figure	3D),	the	initially	negative	relative	growth	rate	appeared	to	gradually	recover	under	constant	drug	
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Overall,	WFABC	identified	64	positively	selected	candidate	mutations,	of	which	24	were	shared	between	at	least	two	populations.	The	allele-frequency	trajectories	of	all	candidate	mutations	across	all	populations	are	plotted	in	Supplementary	Figure	6.	Strikingly,	the	strongest	signal	of	selective	sweeps	(see	also	Supplementary	Figure	5)	and	the	highest	number	of	candidate	mutations	(n=21,	across	passages	3-19)	were	seen	in	the	constA	population,	which	also	showed	signs	of	resistance	evolution	based	on	recovering	growth	rates,	as	detailed	in	the	previous	subsection	(see	Figure	3D);	these	candidates	also	had	the	highest	inferred	selection	coefficients	(see	Supplementary	Table	2).	Of	the	21	candidate	mutations,	10	are	non-synonymous	and	the	majority	(n=8)	are	at	genes	localized	to	the	subunits	of	the	viral	RdRp,	which	could	be	expected	given	that	favipiravir	is	proposed	to	inhibit	the	viral	RdRp	(Furuta	et	al.	2005;	Jin	et	al.	2013).	The	phenotype	of	most	of	the	candidate	mutations	is	unknown.		A	well-characterized	candidate	within	this	group,	NP	S9T,	disrupts	a	phosphorylation	site	and	alters	nuclear-cytoplasmic	shuttling	of	the	nucleoprotein	(NP)	(Hutchinson	et	al.	2012;	Zheng	et	al.	2015).	Phosphorylation	of	NP	S9	prevents	nuclear	import,	and	mutations	at	this	site	thus	lead	to	an	accumulation	of	NP	within	the	nucleus	(Zheng	et	al.	2015),	the	location	of	viral	RNA	replication.	Altering	the	levels	of	NP	in	the	nucleus	could	increase	rates	of	viral	RNA	replication	(Portela	and	Digard	2002),	thereby	counteracting	the	inhibitory	effects	of	favipiravir,	though	this	mechanism	needs	to	be	formally	tested.	Interestingly,	NP	S9	is	perfectly	conserved	in	H1N1	isolates,	and	thus	the	allele	may	be	an	unlikely	resistance	mutation	in	natural	isolates.		Additional	candidate	mutations	were	identified	in	the	constB	population	(n=6).	One	of	the	candidates,	NP	D101N,	was	previously	identified	in	an	
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To	identify	groups	of	mutations	indicative	of	genetic	hitchhiking	and/or	joint	selection	in	the	constA	environment,	we	performed	a	hierarchical	clustering	analysis	based	on	the	squared	Euclidean	distance	between	allele-frequency	trajectories	(see	Materials	&	Methods).	The	result	of	this	analysis	is	illustrated	in	Figure	4.	We	chose	a	dissimilarity	threshold	of	0.95,	which	results	in	six	clusters	(see	Figure	4A).	The	mutations	in	cluster	1	(see	Figure	4B)	begin	to	increase	in	frequency	at	passage	9,	though	come	to	a	halt	(potentially	due	to	interference)	around	passage	13,	which	also	coincides	with	the	increasing	frequency	of	cluster	5.	Two	non-synonymous	mutations	(indicated	with	an	asterisk	in	Figure	4A)	are	the	likely	targets	of	direct	selection	(i.e.,	drivers)	in	this	cluster:	HA	S220P	is	a	mammalian	cell	adaptation	that	has	been	observed	in	MDCK	cells,	ferrets	and	humans	(Smirnov	et	al.	2000;	Ding	et	al.	2010;	Imai	et	al.	2012);	the	same	mutation	is	also	identified	as	a	candidate	in	the	favi2	population.	PB2	G590S	is	a	temperature-sensitive	polymerase	mutation	that	has	been	frequently	observed	upon	switching	from	propagation	of	the	virus	in	chicken	eggs	to	mammalian	cells	(Mehle	and	Doudna	2009;	Poole	et	al.	2014).	Hence,	this	cluster	likely	represents	an	adaptation	to	the	cell	culture.	Cluster	2	contains	only	a	single,	non-synonymous	mutation	in	the	polymerase	subunit	PB2	that	has	not	been	characterized	previously.	The	frequency	of	this	mutation	decreased	towards	the	end	of	the	experiment,	which	may	be	indicative	of	linked	rather	than	direct	selection,	for	example	from	clusters	1	or	3.	Cluster	3	was	the	earliest	to	begin	increasing	in	frequency	in	the	population,	and	several	of	the	mutations	contained	in	this	cluster	were	present	
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early	in	the	experiment	(during	the	phase	of	increasing	drug	concentration;	see	Figure	4D).	The	best-characterized	candidate	and	potential	driver	of	this	cluster	is	NP	S9T	(discussed	above).	However,	an	additional	potentially	interesting	candidate	for	further	study	is	PA	R204R/PA-X	D204G,	which	represents	a	non-synonymous	mutation	in	the	recently	discovered	second	open	reading	frame	of	segment	3,	and	whose	protein	product	has	been	reported	to	be	involved	in	virulence	of	IAV	(Jagger	et	al.	2012).	Cluster	4	is	represented	by	two	mutations	showing	highly	uncharacteristic	allele-frequency	trajectories	(see	Figure	4E).	Given	their	long	persistence	at	intermediate	frequencies,	they	are	unlikely	to	be	driver	mutations.	Cluster	5	contains	the	highest	number	of	mutations,	with	four	being	tightly	linked	in	the	polymerase	subunit	PA.	Most	of	the	involved	mutations	are	synonymous,	making	them	unlikely	driver	candidates.	Two	non-synonymous	mutations	in	PA,	E31G	and	E56G,	have	not	been	previously	characterized.	However,	the	third	non-synonymous	mutation	in	this	cluster,	PB2	K718E	mutates	a	residue	important	in	PB2	binding	to	various	importin	α	isoforms	(α1,	α3	and	α7),	and	thus	is	critical	in	altering	the	kinetics	of	PB2	nuclear	importation	(Pumroy	et	al.	2015).	Combining	this	putative	phenotype	with	that	of	the	NP	S9T	allele	of	cluster	3	suggests	a	model	in	which	adaptation	to	favipiravir	is	associated	with	alteration	of	the	sub-cellular	localization	of	viral	RdRp	components	rather	than	changes	in	viral	RdRp	enzymatic	activity	or	drug	binding.	This	model	is	tentative,	though,	and	warrants	further	investigation.	Finally,	cluster	6	contains	two	mutations,	one	of	which	is	synonymous.	The	other	mutation	is	outside	the	protein-coding	domain	of	the	polymerase	subunit	PB2	and	is	of	unknown	function.	
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CONCLUSION		In	this	study,	we	examined	a	novel	class	of	drug	treatment	that	acts	to	increase	viral	mutation	rates.	Although	an	increased	mutation	rate	may	allow	for	a	more	rapid	appearance	of	beneficial	mutations	in	the	population	(e.g.,	Cirz	and	Romesberg	2007),	the	underlying	notion	is	that	the	comparatively	much	greater	input	rate	of	deleterious	mutations	should	lead	to	population	extinction	(i.e.,	within-host	extinction	of	the	virus)	and	prevent	any	rescue	mutations	from	emerging.	This	expectation	is	supported	by	a	large	body	of	classical	studies	in	evolutionary	theory	that	have	described	the	processes	of	mutational	meltdown	(e.g.,	Lynch	et	al.	1993),	lethal	mutagenesis	(e.g.,	Bull	et	al.	2007;	Martin	and	Gandon	2010;	Arias	et	al.	2014)	and	error	catastrophe	(e.g.,	Biebricher	and	Eigen	2005).		By	comparing	multiple	replicates	of	populations	grown	in	the	absence	of	favipiravir	treatment,	at	constant	concentrations	of	the	drug,	and	at	escalating	concentrations,	we	quantified	the	respective	effects	on	underlying	mutation	rates	and	described	the	resulting	evolutionary	processes.	We	demonstrated	that	all	populations	treated	with	increasing	concentrations	of	favipiravir	were	characterized	by	increased	mutation	rates,	decreasing	effective	population	sizes	through	time,	no	observed	rescue	mutations,	and	ultimate	extinction	in	all	population	replicates	(see	Table	1).	This	pattern	is	in	sharp	contrast	to	populations	treated	with	a	constant	concentration	of	favipiravir,	which	maintain	constant	(but	reduced)	effective	population	sizes,	show	signs	of	selective	sweeps	and,	in	one	replicate,	a	striking	recovery	of	the	population	growth	rate	–	suggesting	that	lower	concentration	conditions	may	indeed	allow	for	the	virus	to	persist	and	potentially	even	develop	resistance.	The	contrast	with	populations	
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favi1 5 yes yes no yes 
favi2 3 yes yes no yes 
constA 18 no yes yes yes 
constB 6 no yes unclear yes 
withdrawalA 1 no yes yes no 		As	the	ultimate	source	of	variation,	mutational	effects	and	rates	have	remained	a	persistent	subject	in	evolutionary	theory.	In	1930,	R.A.	Fisher	(1930)	argued	that	an	intermediate	mutation	rate	is	optimal	for	organisms	to	ensure	a	steady	input	of	beneficial	mutations	while	avoiding	the	detrimental	accumulation	of	deleterious	mutations.	His	arguments	were	later	formalized	in	several	evolutionary	concepts	including	Muller’s	ratchet	(Muller	1964;	Felsenstein	1974),	mutational	meltdown	(Lynch	et	al.,	1990),	lethal	mutagenesis	(Bull	et	al.,	2007),	background	selection	(Charlesworth	et	al.	1993;	Charlesworth	2012),	background	trapping	(Johnson	and	Barton	2002),	Hill-Robertson	
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interference	(Hill	and	Robertson	1966;	McVean	2000),	and,	in	a	more	biophysically	inspired	framework,	quasi-species	theory	(Eigen	1971;	Biebricher	and	Eigen	2005;	but	see	Wilke	2005).	Whereas	these	models	generally	predict	an	eventually	detrimental	effect	of	increasing	the	mutation	rate,	instances	of	rapid	resistance	evolution	against	mutation-rate	increasing	treatment	(Pfeiffer	and	Kirkegaard	2003)	and	a	general	escape	from	extinction	(Springman	et	al.	2010)	have	been	previously	reported.		Furthermore,	so-called	mutator	genotypes	are	frequently	observed	when	bacteria	are	exposed	to	novel	environments,	where	an	increased	mutation	rate	may	facilitate	adaptation,	particularly	over	short	time	scales	(Taddei	et	al.	1997;	Ram	and	Hadany	2012).	Therefore,	efforts	are	made	to	develop	mutation-inhibition	treatments	to	prevent	antibiotic	resistance	evolution	in	bacterial	pathogens	(Cirz	and	Romesberg	2007).	Conversely,	as	demonstrated	here	and	as	previously	argued	theoretically	(e.g.,	Martin	and	Gandon	2010),	increasing	mutation	rates	indeed	also	represent	a	potential	treatment	strategy.		Thus,	the	precise	relevance	of	this	information	for	the	study	of	virus	evolution	and	the	development	of	improved	treatment	strategies	requires	further	examination.	First,	the	correspondence	of	the	observed	patterns	with	classical	theory	demonstrates	the	predictive	value	of	population-genetic	models.	In	the	model	of	Lynch	et	al.	(1993),	extinction	time	is	estimated	based	on	the	mutation	rate,	the	carrying	capacity,	the	rate	of	reproduction,	and	the	selection	coefficient.	Whereas	the	relationship	between	the	reproductive	rate	and	the	carrying	capacity	and	extinction	time	are	relatively	simple,	we	here	present	a	novel	finding	of	the	(deleterious)	selection	coefficient	having	a	non-linear	relationship	with	extinction	time,	a	time	that	is	minimized	under	intermediate	
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selection	coefficients.	This	has	important	implications	for	the	evolution	of	the	virus:	if	changing	the	environment	(e.g.,	drug	pressure)	changes	the	distribution	of	fitness	effects	of	new	mutations,	this	can	result	either	in	shorter	or	longer	extinction	times.	Changing	this	distribution	also	alters	the	relevance	of	the	discussed	evolutionary	mechanisms	(e.g.,	Muller’s	ratchet,	background	selection,	WSHRI).	Essentially,	minimizing	the	expected	extinction	time	optimizes	drug	efficacy	and	decreases	the	risk	of	resistance	evolution.	By	combining	our	emerging	knowledge	of	the	underlying	distributions	of	fitness	effects	of	new	mutations	with	classical	theory,	we	may	be	able	to	develop	better	predictions	regarding	the	efficacy	of	both	single	and	combination	drug	therapies.		Second,	we	observe	that	the	number	of	accumulated	mutations	per	individual	in	the	passage	immediately	prior	to	extinction	was	almost	twice	as	large	in	the	favi1	as	compared	with	the	favi2	population.	This	may	be	partly	explained	by	differences	in	the	experimental	setup	(see	Materials	&	Methods),	but	considering	the	similar	effective	population	sizes	it	more	likely	provides	evidence	for	the	inherent	stochasticity	of	the	extinction	process	(Lynch	et	al.	1993;	Martin	and	Gandon	2010;	Wylie	and	Shakhnovich	2012).	Hence,	it	supports	the	synergism	between	stochastic	and	deterministic	drivers	of	extinction	proposed	in	the	theory	of	mutational	meltdown	(Lynch	et	al.,	1993)	rather	than	error	catastrophe,	which	proposes	extinction	due	to	the	inability	of	the	population	to	contain	information	upon	crossing	a	(sharp)	error	threshold.	Thus,	this	work	is	an	important	empirical	insight	into	the	widely	theorized	models	discussed	above.	Further,	by	experimentally	controlling	the	demographic	dynamics	of	the	population	as	well	as	the	imposed	selective	pressures,	we	avoid	many	of	the	commonly	confounding	effects	encountered	in	
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